Alpheus Medical develops a proprietary sonodynamic therapy platform that pairs Low‑Intensity Diffuse Ultrasound (LIDU™) with oral 5‑ALA, a tumor‑selective sensitizer, to deliver non‑thermal, tumor‑targeted treatment. The therapy is designed to be performed in an outpatient setting and to selectively destroy cancer cells across a brain hemisphere without the need for imaging or sedation. Early results from two studies in newly diagnosed and recurrent glioblastoma patients have shown promise. The company collaborates with global neuro‑oncology leaders and is supported by healthcare investors and nonprofit venture vehicles focused on cancer. Recent financing will fund a randomized Phase 2B controlled trial evaluating SDT’s efficacy in newly diagnosed glioblastoma. Alpheus is based in Chanhassen, Minnesota. Alpheus Medical is developing a non-invasive sonodynamic therapy (SDT) drug-device combination that uses a sonosensitizer activated by low-intensity ultrasound to selectively kill cancer cells. The lead product is designed for outpatient, repeatable whole-hemisphere treatment of recurrent high-grade gliomas, including rGBM, and eliminates the requirement for concomitant imaging. The therapy aims to address the heterogeneous and diffuse nature of glioblastoma by treating both the primary tumor site and diseased tissue throughout the hemisphere. The company reports the therapy is in early clinical stage use and is not yet commercially available. Alpheus has support from the American Cancer Society and the National Brain Tumor Society and is based in Oakdale, Minn. The recently closed financing will be used to advance a multi-site first-in-human trial evaluating safety, feasibility, and molecular and clinical effects.

Total raised

$68M

Funding rounds

2

Latest round

Series B

Latest activity

May 2025